Sanofi will modernize its insulin production facility in Russia

| By | Drug Manufacturing, Sanofi

Sanofi announced a new stage in the modernization of its insulin production facility at Sanofi-Aventis Vostok plant in the Orel region as part of the long-term investment strategy in Russia and confirmed its plans to develop the export capacity of the enterprise.

The plant launched a new inspection machine for high-precision optical control. This is a measuring device for visual inspection of solutions and suspensions in cartridges. The machine performs a two-stage quality control and operates in high-speed mode capable of inspecting up to 400 cartridges per minute. The installation of high-precision equipment allows to significantly increase the efficiency of product quality control (up to 98-99%) and, as a result, improve the performance of the plant.

“For many years, Sanofi has been consistently investing in the modernization of its insulin plant. In 2010, we were one of the first international companies to localize the manufacturing of drugs for the treatment of socially important diseases, which allowed to improve the availability of innovative therapy for Russian patients. Building the export capacity is an important stage in the development of high-tech manufacturing and our contribution to increasing the share of non-commodity exports from Russia,” said Oksana Monge, General Manager, Sanofi Rx Russia and Belarus.

At the beginning of 2018, the plant passed the scheduled EU inspection, which is a prerequisite for insulin exports to EU countries under a special investment contract.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.